British Journal of Haematology最新文献_第9页

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma. MYD88和/或CD79B突变对弥漫性大b细胞淋巴瘤患者中枢神经系统复发的影响

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-22 DOI: 10.1111/bjh.20099

Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga, Hirokazu Sasaki, Takashi Kanamori, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki

{"title":"Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.","authors":"Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga, Hirokazu Sasaki, Takashi Kanamori, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki","doi":"10.1111/bjh.20099","DOIUrl":"https://doi.org/10.1111/bjh.20099","url":null,"abstract":"This study examined the effect of myeloid differentiation primary response gene 88 mutation L265P (MYD88L265P) and/or cluster of differentiation 79B gene mutation Y196 (CD79BY196) (MYD88/CD79B) on central nervous system (CNS) relapse in 270 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Over a median follow-up of 6.65 years, 20 patients experienced CNS relapse. Fifty-five (20%) patients had MYD88/CD79B mutations, and these mutations were significantly associated with an increased risk of CNS relapse in univariable analysis. The overall median time to CNS relapse was 11.5 months, with relapses continuing beyond 2 years in patients harbouring MYD88/CD79B mutations. These patients had 2- and 6-year cumulative CNS relapse rates of 10.9% and 18.1% respectively. Among patients classified as having low or intermediate risk according to the CNS-International Prognostic Index (CNS-IPI), those with MYD88/CD79B mutations exhibited higher CNS relapse rates than those without these mutations (18.8% vs. 1.2%). In contrast, patients with high risk showed high CNS relapse, regardless of the mutation status, suggesting heterogeneous mechanisms underlying CNS relapse. In conclusion, the results of this study suggest that MYD88/CD79B mutations may serve as a predictive marker for CNS relapse in DLBCL, although further validation in additional cohorts is warranted.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience. 资源适应策略在管理儿科伯基特淋巴瘤在低收入和中等收入国家设置和结果：一个印度中心的经验。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-22 DOI: 10.1111/bjh.20093

Garima Nirmal, Priyakumari Thankamony, Rekha A Nair, Manjusha Nair, Binitha Rajeswari, C S Guruprasad, V R Prasanth, Priya Mary Jacob, K M Jagathnath Krishna

{"title":"Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience.","authors":"Garima Nirmal, Priyakumari Thankamony, Rekha A Nair, Manjusha Nair, Binitha Rajeswari, C S Guruprasad, V R Prasanth, Priya Mary Jacob, K M Jagathnath Krishna","doi":"10.1111/bjh.20093","DOIUrl":"https://doi.org/10.1111/bjh.20093","url":null,"abstract":"Burkitt lymphoma (BL) is a challenging cancer to treat in resource-limited settings. We retrospectively analysed 85 BL children ≤14 years, treated during 2007-2017. Median age was 6.5 (2-12) years. Group A, B and C disease was seen in 22%, 48% and 30% respectively. Advanced disease was seen in 78% (stage III 33, stage IV 25). Six children had stage I and 21 had stage II disease. The commonest primary site was the abdomen (56%). Ten children had central nervous system (CNS) and 22 had marrow involvement. Treatment protocols included cyclophosphamide, oncovin, methotrexate, prednisolone (COMP) (United Kingdom Childhood Cancer Study Group) for group A and Multi Centre Protocol 842 (MCP 842) (2007-2008)/modified Lymphomes Malins de Burkitt (LMB) 96 (2009-2017) for group B and C disease. Seventeen children developed tumour lysis syndrome (TLS). Twenty-two children (25%) expired, six from TLS, four from infection and 12 due to disease. Median follow-up was 8.6 (4-15) years. Four-year event-free survival (EFS) and overall survival (OS) were 72.9% and 74.1% respectively. Four-year OS for group A, B, C and stage I, II, III, IV was 100%, 73.2%, 56% (p = 0.005) and 100%, 90.5%, 72.7%, 56% (p = 0.02) respectively. Advanced disease and TLS were significant predictors of inferior EFS on multivariate analysis. We could achieve reasonably good survival in resource-limited settings with judicious use of resources like single-dose rasburicase and modified dose methotrexate.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression. 1q增益/扩增的多发性骨髓瘤通过白细胞介素-6受体过表达显示CD38表达降低。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-22 DOI: 10.1111/bjh.20106

Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi, Sayaka Iwama, Masahiro Yamada, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue, Naoto Takahashi

{"title":"Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression.","authors":"Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi, Sayaka Iwama, Masahiro Yamada, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue, Naoto Takahashi","doi":"10.1111/bjh.20106","DOIUrl":"https://doi.org/10.1111/bjh.20106","url":null,"abstract":"Multiple myeloma (MM) with chromosome 1q21 gain/amplification (1q+) has been reported to respond poorly to daratumumab. We aimed to explore the mechanism of daratumumab resistance in 1q+ MM. Our findings revealed significantly lower CD38 expression in patients with 1q+ MM than in those with 1q wild type (WT) MM. Next, we focused on the interleukin-6 receptor (IL6R) located in the 1q21 region because a previous report shows that interleukin-6 (IL-6) reduces CD38 expression via the IL-6/Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway activation in MM. Indeed, IL6R expression was significantly higher in 1q+ MM than in 1q WT MM. We verified that the 1q+ human myeloma cell lines (HMCLs) expressed higher IL6R levels than the 1q WT HMCLs. IL-6 treatment induced CD38 downregulation in both the 1q+ HMCLs and primary bone marrow (BM) samples but not in their 1q WT HMCLs and BM samples. IL-6 also resulted in the upregulation of phosphorylated STAT3 in 1q+ HMCLs but not in the 1q WT HMCLs. Furthermore, inhibition of the IL-6/JAK/STAT pathway by treatment with ruxolitinib or tocilizumab restored CD38 expression in the 1q+ HMCLs and BM samples. These findings elucidate the mechanisms underlying daratumumab resistance in 1q+ MM and provide insights for future therapeutic strategies.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms. 重度再生障碍性贫血与低危性发育不良骨髓增生异常肿瘤的比较：巨核细胞计数在区分再生障碍性贫血与骨髓增生异常肿瘤中的关键作用。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-22 DOI: 10.1111/bjh.20097

Tomoya Maeda, Akira Matsuda, Junya Kanda, Hiroshi Kawabata, Takayuki Ishikawa, Kaoru Tohyama, Akira Kitanaka, Kayano Araseki, Kei Shimbo, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kensuke Usuki, Maki Shindo-Ueda, Nobuyoshi Arima, Masaharu Nohgawa, Akiko Ohta, Shigeru Chiba, Yasushi Miyazaki, Shinji Nakao, Keiya Ozawa, Shunya Arai, Mineo Kurokawa, Akifumi Takaori-Kondo, Kinuko Mitani

{"title":"Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms.","authors":"Tomoya Maeda, Akira Matsuda, Junya Kanda, Hiroshi Kawabata, Takayuki Ishikawa, Kaoru Tohyama, Akira Kitanaka, Kayano Araseki, Kei Shimbo, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kensuke Usuki, Maki Shindo-Ueda, Nobuyoshi Arima, Masaharu Nohgawa, Akiko Ohta, Shigeru Chiba, Yasushi Miyazaki, Shinji Nakao, Keiya Ozawa, Shunya Arai, Mineo Kurokawa, Akifumi Takaori-Kondo, Kinuko Mitani","doi":"10.1111/bjh.20097","DOIUrl":"https://doi.org/10.1111/bjh.20097","url":null,"abstract":"Although genetic abnormalities are increasingly crucial for diagnosing and classifying haematopoietic diseases, dysplasia remains crucial for distinguishing myelodysplastic neoplasms (MDS) from aplastic anaemia (AA). Erythroid dysplasia may be observed in AA, complicating the differentiation between these conditions. In a previous study using the data from the Japan Idiopathic Myelodysplastic Syndrome Study Group's registry, we found that erythroid dysplasia does not affect the prognosis of AA. This current study was designed to compare the prognosis of patients with lower risk hypoplastic MDS (LR-hMDS), as determined by our review, and patients with severe AA (SAA), all enrolled concurrently, to validate our diagnostic approach. Stringent criteria were used to rule out MDS, considering bone marrow cellularity and megakaryocyte counts, with a confirmed AA diagnosis only following a reduced megakaryocyte count. The study comprised 39 severe cases extracted from a cohort of 100 AA patients previously reported and 41 patients with LR-hMDS. Significant differences in overall and leukaemia-free survival were observed between the two groups (p < 0.0001). Even among patients undergoing immunosuppressive therapy, a marked prognostic distinction became evident after 5 years, although their response to the therapy did not differ significantly. Therefore, the megakaryocyte count is pivotal in differentiating MDS from AA.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How low can we go? Comparison of liberal and restrictive red cell transfusion thresholds in paediatric allogeneic haematopoietic stem cell transplantation: A randomized multicentre feasibility trial. 我们能降到多低？儿童异体造血干细胞移植中自由和限制性红细胞输血阈值的比较：一项随机多中心可行性试验。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-21 DOI: 10.1111/bjh.20051

H V New, E Sanderson, V Hopkins, H Thomas, A Gassas, M Adams, B Gibson, K Patrick, R Wynn, L Hoole, H Smethurst, M Lobo-Clarke, L Smith, A Mora, S J Stanworth

{"title":"How low can we go? Comparison of liberal and restrictive red cell transfusion thresholds in paediatric allogeneic haematopoietic stem cell transplantation: A randomized multicentre feasibility trial.","authors":"H V New, E Sanderson, V Hopkins, H Thomas, A Gassas, M Adams, B Gibson, K Patrick, R Wynn, L Hoole, H Smethurst, M Lobo-Clarke, L Smith, A Mora, S J Stanworth","doi":"10.1111/bjh.20051","DOIUrl":"https://doi.org/10.1111/bjh.20051","url":null,"abstract":"Optimal red blood cell transfusion thresholds for children with bone marrow failure are uncertain; a previous study was stopped following concerns about veno-occlusive disease. The aims of this study in allogeneic haematopoietic stem cell transplant (HSCT) were to assess feasibility of recruitment and protocol adherence (primary outcomes) for different haemoglobin (Hb) transfusion thresholds, and to describe safety and present exploratory data on quality of life (QoL). Children aged ≥1 to <18 years were randomized to restrictive Hb transfusion thresholds of 65 g/L (restrictive) vs. 80 g/L (liberal) for HSCT days 0-100. Thirty-four patients were randomized at four UK HSCT centres, 17 in each arm. 48.6% (34/70) of eligible patients were recruited (target ≥50%), with high levels of protocol adherence: % (n/N) [95% CI] in the restrictive and liberal arms were 99.2 (961/969) [98.6, 99.7] and 97.2 (1131/1164) [96.2, 98.1] respectively (target ≥70% each arm). The mean pre-transfusion Hb was 16.3 g/L higher in the liberal than in the restrictive arm. Feasibility to measure QoL was demonstrated with no evidence of more fatigue in the restrictive arm. Although the study was not powered for clinical outcomes, the findings suggest that some populations may be able to safely tolerate anaemia levels below 70 g/L, the most common restrictive transfusion threshold.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemia. 新型MYD88突变，6q缺失的Waldenström巨球蛋白血症BCWM.2细胞系的开发和特性

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-20 DOI: 10.1111/bjh.20072

Shirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, Amanda Kofides, Kara M Soroko, Johany Penailillo, Alexa G Canning, Yang Cao, Guang Yang, Lian Xu, Nicholas Tsakmaklis, Hao Sun, Alberto Guijosa, Maria L Guerrera, Christopher J Patterson, Ruben D Carrasco, Prafulla C Gokhale, Shayna R Sarosiek, Jorge J Castillo, John M Hatcher, Zachary R Hunter, Steven P Treon

{"title":"Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemia.","authors":"Shirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, Amanda Kofides, Kara M Soroko, Johany Penailillo, Alexa G Canning, Yang Cao, Guang Yang, Lian Xu, Nicholas Tsakmaklis, Hao Sun, Alberto Guijosa, Maria L Guerrera, Christopher J Patterson, Ruben D Carrasco, Prafulla C Gokhale, Shayna R Sarosiek, Jorge J Castillo, John M Hatcher, Zachary R Hunter, Steven P Treon","doi":"10.1111/bjh.20072","DOIUrl":"https://doi.org/10.1111/bjh.20072","url":null,"abstract":"Cell lines have enabled a comprehensive understanding of disease biology and the advancement of new therapeutics in Waldenström macroglobulinaemia (WM). Herein, we report the development of BCWM.2, a novel WM cell line derived from an untreated symptomatic WM patient. Immunophenotypic and genomic analyses confirmed its origin from primary bone marrow WM cells. Flow cytometry revealed expression of CD19, CD20, CD23, CD38, CD45RA, CD52, immunoglobulin M (IgM) heavy chain and λ light chain on BCWM.2 cells. Whole genome sequencing demonstrated that, unlike BCWM.1, MWCL-1 and RPCI-WM1, which harbour MYD88L265P mutations, BCWM.2 carries MYD88S243N. BCWM.2 also exhibited hallmark WM genetic aberrations, including 6q deletion and 6p amplification, along with unique mutations in LYN, AKAP9, HDAC5, RUNX3 and SPI1. BCWM.2 cells exhibited optimal growth when co-cultured with HS-5 stromal cells and developed subcutaneous flank masses in all five NOD-SCID mice, along with measurable serum human IgM levels. BCWM.2 cells also showed remarkable sensitivity to the B-cell lymphoma 2 inhibitor venetoclax and the Janus kinase 2/Interleukin-1 receptor-associated kinase 1 inhibitor pacritinib, underscoring their utility for identification of pharmacologically active agents. BCWM.2 represents a novel myeloid differentiation primary response 88-mutated, 6q-deleted cell line with distinct genomic features for in vivo and in vitro studies for WM.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PF4 promotes CXCR3⁺ Tfh1 cell differentiation through STAT1 in mouse immune thrombocytopenia. PF4在小鼠免疫性血小板减少症中通过STAT1促进CXCR3+ Tfh1细胞分化。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-16 DOI: 10.1111/bjh.20090

Lei Hai, Yi Zheng, Ziyin Yang, Siwen Wu, Yan Lv, Dawei Cui, Jue Xie

引用次数: 0

Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. 现实世界数据中SKY92基因表达谱增强多发性骨髓瘤的风险分层和治疗决策

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-15 DOI: 10.1111/bjh.20050

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Divaya Bhutani, John T McKay, David H Vesole, Ajay Nooka, Barry Paul, Parameswaran N Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David Siegel, Saad Z Usmani, Frits van Rhee

{"title":"Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data.","authors":"Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Divaya Bhutani, John T McKay, David H Vesole, Ajay Nooka, Barry Paul, Parameswaran N Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David Siegel, Saad Z Usmani, Frits van Rhee","doi":"10.1111/bjh.20050","DOIUrl":"https://doi.org/10.1111/bjh.20050","url":null,"abstract":"Over the years, numerous prognostic markers for multiple myeloma (MM) risk classification have been identified; however, their variability can lead to inconsistent clinical interpretations. Gene expression profiling (GEP) signatures, such as SKY92, offer a more accurate method for patient stratification. The PRospective Observational Multiple Myeloma Impact Study (NCT02911571) aimed to validate SKY92's prognostic performance using real-world data and assess its impact on risk classification and treatment decisions compared to conventional markers. In a study of 251 newly diagnosed MM patients, physicians completed questionnaires to capture risk classification, hypothetical treatment plans and their confidence in those plans before and after unblinding SKY92 results. Poor concordance was observed between initial clinical risk assessment (iCRA) and SKY92 results (high risk: 51% iCRA vs. 28% SKY92, Cohen's κ = 0.21). SKY92 showed superior performance in identifying high-risk patients, leading to better predictions of progression-free survival and overall survival (p ≤ 0.0001) than traditional risk markers. Unblinding SKY92 results led to hypothetical treatment revisions for 50% of patients (p < 0.001) and increased physicians' confidence in treatment decisions for 40% of cases. These findings support SKY92's prognostic value in identifying high-risk MM patients, outperforming traditional risk markers and demonstrating the potential added value of its integration into clinical practice for more personalized risk assessment.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understandings 18 FDG PET radiomics and its application to lymphoma. FDG PET放射组学及其在淋巴瘤中的应用。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-15 DOI: 10.1111/bjh.20074

Luca Ceriani, Lisa Milan, Stephane Chauvie, Emanuele Zucca

{"title":"Understandings 18 FDG PET radiomics and its application to lymphoma.","authors":"Luca Ceriani, Lisa Milan, Stephane Chauvie, Emanuele Zucca","doi":"10.1111/bjh.20074","DOIUrl":"https://doi.org/10.1111/bjh.20074","url":null,"abstract":"The early identification of lymphoma patients who fail front-line treatment is crucial for optimizing disease management. Positron emission tomography, a well-established tool for staging and response evaluation in lymphoma, is typically assessed visually or semiquantitatively, leaving much of its latent information unexploited. Radiomic analysis, which employs mathematical descriptors, can enable the extraction of quantitative features from baseline images that correlate with the disease's biological characteristics. Emerging radiomic features such as metabolic tumour volume, total lesion glycolysis and markers of disease dissemination and metabolic heterogeneity are proving to be powerful prognostic biomarkers in lymphoma. Texture analysis, the most advanced area of radiomics, offers highly complex features that require further standardization and validation before being adopted as reliable biomarkers. Combining radiomic features with clinical risk factors and genomic data holds promising potential for improving clinical risk prediction. This review explores the current state of radiomic analysis, progress towards its standardization and its incorporation into clinical practice and trial designs. The integration of radiomic markers with circulating tumour DNA may provide a comprehensive approach to developing baseline and dynamic risk scores, facilitating the testing of novel treatments and advancing personalized treatment of aggressive lymphomas.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The molecular landscape of AL amyloidosis AL淀粉样变的分子景观

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2025-04-11 DOI: 10.1111/bjh.20070

Tal Zvida-Bloch, Eli Muchtar, Angela Dispenzieri, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

{"title":"The molecular landscape of AL amyloidosis","authors":"Tal Zvida-Bloch, Eli Muchtar, Angela Dispenzieri, Ofer Shpilberg, Oshrat Hershkovitz-Rokah","doi":"10.1111/bjh.20070","DOIUrl":"https://doi.org/10.1111/bjh.20070","url":null,"abstract":"Amyloid light-chain (AL) amyloidosis is a systemic clonal plasma cell disorder characterized by the production and deposition of misfolded immunoglobulin light chains (LCs), resulting in multiorgan dysfunction. Due to its intricate molecular mechanisms and diverse organ involvement, the disease poses significant diagnostic and therapeutic challenges. This review explores the molecular landscape of AL amyloidosis, emphasizing genetic, transcriptomic and proteomic alterations. Key findings include chromosomal abnormalities, somatic mutations, aberrant gene expression, disrupted protein folding pathways and the role of cytokine and chemokine secretion. These factors collectively drive the overproduction and destabilization of amyloidogenic LCs, leading to organ-specific amyloid deposition, clinical heterogeneity and variable patient outcomes. Despite therapeutic advancements, the disease's complexity challenges the development of effective biological models. Progressing towards personalized therapies requires the development of preclinical models and the identification of biomarkers and molecular data to design targeted interventions. This review highlights the importance of integrating DNA, RNA and protein-level analyses to deepen the understanding of AL amyloidosis pathogenesis. Such insights are pivotal for improving diagnostics, prognostics and therapeutic strategies, ultimately advancing precision medicine for this challenging disease.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 5","pages":"1297-1311"},"PeriodicalIF":5.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.20070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143949940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0